drugset

Drugs / second generation 4-1BBζ B7H3-EGFRt-DHFR

Follow last change Sep 2024 re-read 3 minutes ago

second generation 4-1BBζ B7H3-EGFRt-DHFR

Developed for: childhood malignant neoplasm · clear cell sarcoma · desmoplastic small round cell tumor · Ewing sarcoma · germ cell tumor · hepatoblastoma · malignant peripheral nerve sheath tumor · melanoma
+7 more
· neuroblastoma · osteosarcoma · retinoblastoma · rhabdoid tumor · rhabdomyosarcoma · synovial sarcoma · Wilms tumor
Investigated by: Seattle Children's Hospital

Trials 1

today NCT04483778 · Ph 1

2020202120222023202420252026202720282029203020312032203320342035203620372038203920402041

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 1	NCT04483778	Jul 2020 → Dec 2040 expected	Ewing sarcoma, Wilms tumor, childhood malignant neoplasm, clear cell sarcoma +11	Seattle Children's Hospital	Active not recruiting	No outcome recorded

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 2 sources stand behind the page.

Field	Value	Cited text
Known as	second generation 4-1BBζ B7H3-EGFRt-DHFR	ClinicalTrials.gov intervention name — accepted as the source's own label NCT04483778 ↗
Action	Deplete	“target and kill solid tumors that express B7H3” NCT04483778 ↗
Modality	Cell therapy	“B7-H3 chimeric antigen receptor (CAR) T cells” PMID 39255444 ↗ Sep 2024
Route	Other	“systemically administered B7-H3 chimeric antigen receptor (CAR) T cells” PMID 39255444 ↗ Sep 2024